{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:15:44Z","timestamp":1775592944907,"version":"3.50.1"},"reference-count":27,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CCID"],"DOI":"10.2147\/ccid.s442437","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T23:45:20Z","timestamp":1698277520000},"page":"2911-2917","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the Clinical Assessment, Guidelines, and Options for the Treatment of Generalized Pustular Psoriasis [Podcast]"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Eingun James","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"Navarini","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/PTT.S181808","volume":"9","author":"Ly","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","volume":"23","author":"Marrakchi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref4","first-page":"669","volume":"16","author":"Augey","year":"2006","journal-title":"Eur J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/PTT.S98954","volume":"6","author":"Benjegerdes","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jdv.18720","volume":"37","author":"Prinz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40257-021-00653-0","volume":"23","author":"Burden","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/jdv.18999","volume":"37","author":"Burden","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","volume":"67","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"Fujita","year":"2018","journal-title":"J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/jdv.16684","volume":"34","author":"Lambert","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-021-00652-1","volume":"23","author":"Fujita","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jdv.18851","volume":"37","author":"Puig","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref16","unstructured":"Boehringer Ingelheim. FDA approves the first treatment option for generalized pustular psoriasis flares in adults. (September 01, 2022) Available at: https:\/\/www.boehringer-ingelheim.us\/press-release\/fda-approves-first-treatment-option-generalized-pustular-psoriasis-flares-adults. Accessed July 20, 2023."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","volume":"23","author":"Krueger","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1744666X.2021.1961580","volume":"17","author":"Komine","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/1744666X.2022.2116003","volume":"18","author":"Bachelez","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"ref20","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of positive opinion: Spevigo (spesolimab). (2022). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/spevigo. Accessed July 20, 2023."},{"key":"ref21","unstructured":"Boehringer Ingelheim. SPEVIGO prescribing information. (September 2022) Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761244s000lbl.pdf. Accessed July 20, 2023."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMc1811317","volume":"380","author":"Bachelez","year":"2019","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s13555-022-00830-x","volume":"12","author":"Shao","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01378-8","author":"Morita","year":"2023","journal-title":"Lancet"},{"key":"ref26","unstructured":"Gudjonsson JE, Reich A, Barker JN, et al. Imsidolimab, an anti-IL-36 receptor monoclonal antibody, in the treatment of generalized pustular psoriasis: results from a Phase 2 trial. Presented at: 30th EADV Congress; 29 September\u20132 October 2021. (Virtual)."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Gudjonsson J, Randazzo B, Zhou J, Peterson R, Lizzul P. Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: design of a pivotal Phase 3 clinical trial and a long-term extension study. Presented at: the 2022 Annual Meeting of the American Academy of Dermatology (AAD); Boston, MA, US; March 25\u201329, 2022. Abstract\/Poster 34617.","DOI":"10.1016\/j.jaad.2022.06.313"}],"container-title":["Clinical, Cosmetic and Investigational Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=93749","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=93749","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T23:45:26Z","timestamp":1698277526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/exploring-the-clinical-assessment-guidelines-and-options-for-the-treat-peer-reviewed-fulltext-article-CCID"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":27,"URL":"https:\/\/doi.org\/10.2147\/ccid.s442437","relation":{},"ISSN":["1178-7015"],"issn-type":[{"value":"1178-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}